Tags

Type your tag names separated by a space and hit enter

Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
J Clin Invest. 2005 Dec; 115(12):3400-3.JCI

Abstract

The recent discovery of the G(i) protein-coupled receptor GPR109A (HM74A in humans; PUMA-G in mice) as a receptor for nicotinic acid has provided the opportunity to gain greater understanding of the underlying biology contributing to the clinical efficacy (increases in HDL, decreases in VLDL, LDL, and triglycerides) and the characteristic side-effect profile of nicotinic acid. GPR109A has been proven to be the molecular target for the actions of nicotinic acid on adipose tissue, and in this issue of the JCI, Benyó et al. have confirmed the involvement of GPR109A in the nicotinic acid-induced flushing response, a common side effect. The involvement of GPR109A in both the desirable and undesirable clinical actions of nicotinic acid raises interesting questions regarding the function of this receptor.

Authors+Show Affiliations

Atherosclerosis Department, GlaxoSmithKline, Stevenage, UK. Nick.B.Pike@gsk.com

Pub Type(s)

Comment
Journal Article

Language

eng

PubMed ID

16322787

Citation

Pike, Nicholas B.. "Flushing Out the Role of GPR109A (HM74A) in the Clinical Efficacy of Nicotinic Acid." The Journal of Clinical Investigation, vol. 115, no. 12, 2005, pp. 3400-3.
Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest. 2005;115(12):3400-3.
Pike, N. B. (2005). Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. The Journal of Clinical Investigation, 115(12), 3400-3.
Pike NB. Flushing Out the Role of GPR109A (HM74A) in the Clinical Efficacy of Nicotinic Acid. J Clin Invest. 2005;115(12):3400-3. PubMed PMID: 16322787.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. A1 - Pike,Nicholas B, PY - 2005/12/3/pubmed PY - 2006/2/7/medline PY - 2005/12/3/entrez SP - 3400 EP - 3 JF - The Journal of clinical investigation JO - J Clin Invest VL - 115 IS - 12 N2 - The recent discovery of the G(i) protein-coupled receptor GPR109A (HM74A in humans; PUMA-G in mice) as a receptor for nicotinic acid has provided the opportunity to gain greater understanding of the underlying biology contributing to the clinical efficacy (increases in HDL, decreases in VLDL, LDL, and triglycerides) and the characteristic side-effect profile of nicotinic acid. GPR109A has been proven to be the molecular target for the actions of nicotinic acid on adipose tissue, and in this issue of the JCI, Benyó et al. have confirmed the involvement of GPR109A in the nicotinic acid-induced flushing response, a common side effect. The involvement of GPR109A in both the desirable and undesirable clinical actions of nicotinic acid raises interesting questions regarding the function of this receptor. SN - 0021-9738 UR - https://www.unboundmedicine.com/medline/citation/16322787/Flushing_out_the_role_of_GPR109A__HM74A__in_the_clinical_efficacy_of_nicotinic_acid_ DB - PRIME DP - Unbound Medicine ER -